-- Preclinical data continues to demonstrate PAS-004’s potentially superior properties as compared to FDA approved MEK inhibitors -- -- Once daily dose of PAS-004 delivers anti-tumor efficacy in in vivo NRAS mutation cancer models -- SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp.

--临床前数据继续证明，与FDA批准的MEK抑制剂相比，PAS-004具有潜在的优越性能--PAS-004的每日一次剂量在体内NRAS突变癌症模型中提供抗肿瘤功效--加利福尼亚州南旧金山和迈阿密，2023年12月11日（环球新闻网）--Pasithea Therapeutics Corp。

(NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, today announced positive preclinical results from two in vivo studies evaluating the anti-tumor efficacy of PAS-004 in NRAS mutation cancer xenograft models.

（纳斯达克：KTTA）（“Pasithea”或“公司”）是一家专注于发现，研究和开发中枢神经系统（CNS）疾病创新治疗方法的生物技术公司，今天宣布了两项体内研究的阳性临床前结果，评估了PAS-004在NRAS突变癌症异种移植模型中的抗肿瘤功效。

In the first study, PAS-004 exhibited dose-dependent anti-tumor efficacy in the lung cancer NCI-H1299 cell-line-derived xenograft model. PAS-004 at dose levels of 10 mg/kg and 5 mg/kg, once daily, significantly inhibited tumor growth as compared to vehicle control. The anti-tumor efficacy of PAS-004, when taken at equivalent doses was shown to be superior to that of binimetinib and selumetinib.

在第一项研究中，PAS-004在肺癌NCI-H1299细胞系衍生的异种移植模型中表现出剂量依赖性的抗肿瘤功效。与载体对照相比，每天一次剂量水平为10 mg/kg和5 mg/kg的PAS-004显着抑制肿瘤生长。当以相同剂量服用时，PAS-004的抗肿瘤功效显示优于binimetinib和selumetinib。

In the second study, PAS-004 exhibited dose-dependent anti-tumor efficacy in the liver cancer xHepG2 cell-line-derived xenograft model. PAS-004 at dose levels of 10 mg/kg and 5 mg/kg, once daily, produced signigicant antitumor activities as compared to vehicle control. The anti-tumor efficacy of PAS-004, when taken at equivalent doses was shown to be similar to that of binimetinib and superior to that of selumetinib.

在第二项研究中，PAS-004在肝癌xHepG2细胞系衍生的异种移植模型中表现出剂量依赖性的抗肿瘤功效。与媒介物对照相比，剂量水平为10 mg/kg和5 mg/kg的PAS-004每天一次产生显着的抗肿瘤活性。当以相同剂量服用时，PAS-004的抗肿瘤功效显示与binimetinib相似，并且优于selumetinib。

These studies were conducted to provide further support of PAS-004 ahead of the Company’s planned first-in-human Phase 1 open-label dose escalation trial in patients with MAPK pathway-driven advanced solid tumors harboring RAS, RAF or NF1 mutations or patients who have failed BRAF/MEK inhibitio.

这些研究旨在为PAS-004提供进一步的支持，这是该公司计划在MAPK途径驱动的晚期实体瘤患者（携带RAS，RAF或NF1突变）或BRAF/MEK抑制失败的患者中进行的首次人类1期开放标签剂量递增试验。